Endo Pharmaceuticals presents new phase 2 data evaluating XIAFLEX®
Endo Pharmaceuticals announced new data evaluating safety and efficacy of XIAFLEX® (collagenase clostridium histolyticum) injection under investigation for treatment of palmar Dupuytren's disease nodules. September 30, 2016